

(use several sheets if necessary)

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)


FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

[illegible]

EXAMINER: 	DATE CONSIDERED: 12/20/06
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449

Attorney's Docket No. 128019-203801

Application Serial No. 09/700,101

INFORMATION DISCLOSURE STATEMENT

Applicant(s)

Gary D. GLICK, et al.

Filing Date: November 8, 2000

Group Art Unit: Unassigned

(use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.	02/28/1978	4,076,823	Wade, et al.			
	2.	08/29/1978	4,110,327	Szarvasi			
	3.	01/22/1985	4,495,104	Klaubert, et al.			
	4.	06/14/1988	4,751,223	Glamkowski, et al.			
	5.	08/20/1991	5,041,438	Hsu			
	6.	06/28/1994	5,324,726	Bock, et al.			
	7.	01/28/1997	5,597,915	Chambers, et al.			
	8.	07/07/1998	5,776,946	McGeer, et al.			
	9.	01/19/1999	5,861,380	Gyorkos, et al.			
	10.	12/21/1999	6,004,942	Firestein, et al.			
	11.	06/27/2000	6,080,588	Glick			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation
	12.	06/04/2000	WO 00/19200	PCT			YES NO

OTHER DOCUMENTS

(including author's abstracts, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
	13.	Adachi, M., et al., "Aberrant Transcription Caused by the Insertion of an Early Transposable Element in an Intron of the Fas Antigen Gene of <i>lpr</i> Mice," <i>Proc. Natl. Acad. Sci. USA</i> - 90:1756-1760 (1993)
	14.	Adelman, N.E., et al., "Treatment of (NZB X NZW)F ₁ Disease with Anti-I-A Monoclonal Antibodies," <i>J. Exp. Med.</i> - 158:1350-1355 (1983)
	15.	Baader, S.L., et al., "Uptake and Cytotoxicity of Ascorbic Acid and Dehydroascorbic Acid in Neuroblastoma (SK-N-SH) and Neuroectodermal (SK-N-LO) Cells," <i>Anticancer Research</i> - 14:221-228 (1994)
	16.	Beale, P.J., et al., "BCL-2 Family Protein Expression and Platinum Drug Resistance in Ovarian Carcinoma," <i>British Journal of Cancer</i> - 82(2):436-440 (2000)
	17.	Boojamra, C.G., et al., "Solid-Phase Synthesis of 1,4-Benzodiazepine-2,5-Diones. Library Preparation and Demonstration of Synthesis Generality," <i>J. Org. Chem.</i> - 62:1240-1256 (1997)
	18.	Bunin, B.A., et al., "A General and Expedient Method for the Solid-Phase Synthesis of 1,4-Benzodiazepine Derivatives," <i>J. Am. Chem. Soc.</i> - 114:10997-10998 (1992)
	19.	Bunin, B.A., et al., "The Combinatorial Synthesis and Chemical and Biological Evaluation of a 1,4-Benzodiazepine Library," <i>Proc. Natl. Acad. Sci. USA</i> - 91:7408-7412 (1994)
	20.	Chumakov, A.M., et al., "Analysis of p53 Transactivation Through High-Affinity Binding Sites," <i>Oncogene</i> - 8:3005-3011 (1993)
	21.	Cohen, P.L., et al., " <i>Lpr</i> and <i>gld</i> : Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease," <i>Annu. Rev. Immunol.</i> - 9:243-269 (1991)
	22.	Crabtree, R.H., "A New Type of Hydrogen Bond," <i>Science</i> - 282:2000-2001 (1998)
	23.	Desoize, B., "Anticancer Drug Resistance and Inhibition of Apoptosis," <i>Anticancer Research</i> - 14:2291-2294 (1994)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not considered. Include a copy of this form with next communication to applicant.

154157.1

193696v1

Form PTO-1449	Attorney's Docket No. 128019-203801	Application Serial No. 09/700,101
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Gary D. GLICK, et al.	
	Filing Date: November 8, 2000	Group Art Unit: Unassigned
(use several sheets if necessary)		

OTHER DOCUMENTS (Continuation)

(including author, title, date, pertinent pages, etc.)

24. Dobie, A., et al., "Labelling of Peripheral-Type Benzodiazepine Binding Sites in Human Brain with [PH]PK 11195: Anatomical and Subcellular Distribution," *Brain Research Bulletin* - 18:49-61 (1987)
25. Donadio, J.V., et al., "Immunosuppressive Drug Therapy in Lupus Nephritis," *American Journal of Kidney Diseases* - 21(3):239-250 (1993)
26. Ermak, T.H., et al., "Treatment of Murine Lupus with Monoclonal Antibody to L3T4," *Laboratory Investigation* - 61(4):447-458 (1989)
27. Gallant, J.E., et al., "Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine," *The Journal of Infectious Diseases* - 166:1223-1227 (1992)
28. Garcia-Calvo, M., et al., "Inhibition of Human Caspases by Peptide-Based and Macromolecular Inhibitors," *The Journal of Biological Chemistry* - 273(49):32608-32613 (1998)
29. Gorczyca, W., et al., "Induction of DNA Strand Breaks Associated with Apoptosis During Treatment of Leukemias," *Leukemia* - 7(5):659-670 (1993)
30. Gordon, C., et al., "Chronic Therapy with Recombinant Tumor Necrosis Factor- α in Autoimmune NZB/NZW F₁ Mice," *Clinical Immunology and Immunopathology* - 52:421-434 (1989)
31. Gordon, E.M., et al., "Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," *Journal of Medicinal Chemistry* - 37(10):1385-1401 (1994)
32. Hahn, B.H., et al., "Influence of Cyclophosphamide and Other Immunosuppressive Drugs on Immune Disorders and Neoplasia in NZB/NZW Mice," *Arthritis and Rheumatism* - 18(2):145-152 (1975)
33. Hang, L., et al., "A Spontaneous Rheumatoid Arthritis-Like Disease in MRL/lpr Mice," *J. Exp. Med.* - 155:1690-1701 (1982)
34. Horowitz, R.E., et al., "Cyclophosphamide Treatment of Mouse Systemic Lupus Erythematosus," *Laboratory Investigation* - 21(3):199-206 (1969)
35. Itoh, N., et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," *Cell* - 66:233-243 (1991)
36. Koopman, W.J., et al., "The MRL-lpr/lpr Mouse. A Model for the Study of Rheumatoid Arthritis," *Scand. J. Rheumatology* - Suppl 75:284-289 (1988)
37. Korsmeyer, S.J., "Bcl-2 Initiates a New Category of Oncogenes: Regulators of Cell Death," *Blood* - 80(4):879-886 (1992)
38. Lu, J.R., et al., "Bcl-x_L is Expressed in Ovarian Carcinoma and Modulates Chemotherapy-Induced Apoptosis," *Gynecologic Oncology* - 70:398-403 (1998)
39. Los, M., et al., "The Role of Caspases in Development, Immunity, and Apoptotic Signal Transduction: Lessons from Knockout Mice," *Immunity* - 10:629-639 (1999)
40. Luria, et al., "General Virology - 3rd edition, pp. 436-446 (1978) - Eds. John Wiley & Sons, New York
41. Marino, M., et al., "Prevention of Systemic Lupus Erythematosus in MRL/lpr Mice by Administration of an Immunoglobulin-Binding peptide," *Nature Biotechnology* - 18:735-739 (2000)
42. McDonnell, T.J., et al., "Progression from Lymphoid Hyperplasia to High-Grade Malignant Lymphoma in Mice Transgenic for the t(14;18)," *Nature* - 349:254-256 (1991)
43. Nagata, S., "Human Autoimmune Lymphoproliferative Syndrome, a Defect in the Apoptosis-Inducing Fas Receptor: A Lesson from the Mouse Model," *J. Hum. Genet.* - 43:2-8 (1998)
44. Okuyama, H., et al., "Analysis of Defective Delayed-Type Hypersensitivity in Autoimmune Mice Bearing lpr Gene," *Clin. Exp. Immunol.* - 63:87-94 (1986)
45. Okuyama, H., et al., "Effect of Cyclophosphamide Pretreatment on Defective Delayed-Type Hypersensitivity in Autoimmune-Prone MRL Mice," *Int. Arch. Allergy Appl. Immunol.* - 88:394-401 (1989)

EXAMINER:

DATE CONSIDERED: 12/20/06

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance not considered. Include a copy of this form with next communication to applicant.

154157.1

193696v1

Form PTO-1449

Attorney's Docket No. 128019-203801

Application Serial No. 09/700,101

INFORMATION DISCLOSURE STATEMENT

Applicant(s)

Gary D. GLICK, et al.

Filing Date: November 8, 2000

Group Art Unit: Unassigned

(use several sheets if necessary)

OTHER DOCUMENTS (Continuation)

(including author, date, pertinent pages, etc.)

46. Ozols, R.F., "Paclitaxel Plus Carboplatin in the Treatment of Ovarian Cancer," *Seminars in Oncology* - 26(1)(Supp. 2):84-89 (1999)
47. Pestell, K.E., et al., "Characterisation of the P53 Status, BCL-2 Expression and Radiation and Platinum Drug Sensitivity of a Panel of Human Ovarian Cancer Cell Lines," *Int. J. Cancer* - 77:913-918 (1998)
48. Raynaud, F.I., et al., "Intracellular Metabolism of the Orally Active Platinum Drug JM216: Influence of Glutathione Levels," *Br. J. Cancer* - 74(3):380-386 (1996)
49. Russell, J.H., et al., "Mature T Cells of Autoimmune lpr/lpr Mice have a Defect in Antigen-Stimulated Suicide," *Proc. Natl. Acad. Sci. USA* - 90:4409-4413 (1993)
50. Sakata, K., et al., "Role of Fas/FasL Interaction in Physiology and Pathology: The Good and the Bad," *Clinical Immunology and Immunopathology* - 87(1):1-7 (1998)
51. Sandstrom, P.A., et al., "Autocrine Production of Extracellular Catalase Prevents Apoptosis of the Human CEM T-Cell Line in Serum-Free Medium," *Proc. Natl. Acad. Sci. USA* - 90:4708-4712 (1993)
52. Schoemaker, H., et al., "Specific High-Affinity Binding Sites for [³H]Ro5-4864 in Rat Brain and Kidney," *The Journal of Pharmacology and Experimental Therapeutics* - 225(1):61-69 (1983)
53. Schwab, M., et al., "Amplified DNA with Limited Homology to *myc* Cellular Oncogene is Shared by Human Neuroblastoma Cell Lines and a Neuroblastoma Tumour," *Nature* - 305:245-248 (1983)
54. Scott, C.F., et al., "Comparison of Antigen-Specific T Cell Responses in Autoimmune MRL/mp-lpr/lpr and MRL/Mp-+/+ Mice," *The Journal of Immunology* - 132(2):633-639 (1984)
55. Sentman, C.L., et al., "bcl-2 Inhibits Multiple Forms of Apoptosis but not Negative Selection in Thymocytes," *Cell* - 67:879-888 (1991)
56. Sheppard, R.C., et al., "Acid-Labile Resin Linkage Agents for Use in Solid Phase Peptide Synthesis," *Int. J. Peptide Protein Res.* - 20:451-454 (1982)
57. Stevens, S.Y., et al., "Non Nucleic Acid Inhibitors of Protein-DNA Interactions Identified Through Combinatorial Chemistry," *J. Am. Chem. Soc.* - 118:10650-10651 (1996)
58. Sugimoto, T., et al., "Determination of Cell Surface Membrane Antigens Common to Both Human Neuroblastoma and Leukemia-Lymphoma Cell Lines by a Panel of 38 Monoclonal Antibodies," *JNCI* - 73(1):51-57 (1984)
59. Swanson, P.C., et al., "High Resolution Epitope Mapping of an Anti-DNA Autoantibody Using Model DNA Ligands," *J. Immunology* - 152(5):2601-2612 (1994)
60. Swanson, P.C., et al., "Ligand Recognition by Murine Anti-DNA Autoantibodies," *J. Clin. Invest.* - 97(7):1748-1760 (1996)
61. Takahashi, T., et al., "Generalized Lymphoproliferative Disease in Mice, Caused by a Point Mutation in the Fas Ligand," *Cell* - 76:969-976 (1994)
62. Theofilopoulos, A.N., et al., "Murine Models of Systemic Lupus Erythematosus," *Advances in Immunology* - 37:269-390 (1985)
63. Thompson, C.B., "Apoptosis in the Pathogenesis and Treatment of Disease," *Science* - 267:1456-1462 (1995)
64. Watanabe-Fukunaga, R., et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis," *Nature* - 356:314-317 (1992)
65. White, E., "Life, Death, and the Pursuit of Apoptosis," *Genes & Development* - 10:1-15 (1996)
66. Wu, G.Y., et al., "Receptor-Mediated *In Vitro* Gene Transformation by a Soluble DNA Carrier System," *The Journal of Biological Chemistry* - 262(10):4429-4432 (1987)
67. Wyllie, A.H., "The Genetic Regulation of Apoptosis," *Current Opinion in Genetics & Development* - 5:97-104 (1995)
68. Zamzami, N., et al., "Mitochondrial Control of Nuclear Apoptosis," *J. Exp. Med.* - 183:1533-1544 (1996)
69. Zoratti, M., et al., "The Mitochondrial Permeability Transition," *Biochimica et Biophysica Acta* - 1241:139-176 (1995)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformity. Include a copy of this form with next communication to applicant.

154157.1

193696v1

Gary D. GLICK, et al.

Group Art Unit: Unassigned

(use several sheets if necessary)

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation is considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance. Include a copy of this form with next communication to applicant.

154157.1

194748v1